| Autor: |
Dong, Ning, Rubio Lopes-Garcia, Lucía, Viñal, David, Bachmeier, Christina, Shah, Bijal D., Nishihori, Taiga, Khimani, Farhad, Davila, Marco L., Lazaryan, Aleksandr, Pinilla-Ibarz, Javier, Locke, Frederick L., Jain, Michael D., Chavez, Julio C. |
| Zdroj: |
Transplantation and Cellular Therapy; June 2023, Vol. 29 Issue: 6 p349.e1-349.e8, 8p |
| Abstrakt: |
•Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) showed efficacy in relapsed/refractory transformed nonfollicular lymphomas (tNFLs), including transformed marginal zone lymphoma and transformed chronic lymphocytic leukemia/small lymphocytic lymphoma, comparable to de novo diffuse large B cell lymphoma and transformed follicular lymphoma, supporting their use in this patient population.•Most patients tolerated treatment, although 2 patients died from treatment-related side effects after axi-cel.•Ibrutinib used concurrently with tisa-cel in tNFL was tolerated by 6 patients. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect